A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.

Trial Profile

A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 May 2013

At a glance

  • Drugs Erlotinib (Primary) ; Linsitinib (Primary) ; Goserelin; Letrozole
  • Indications Advanced breast cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Nov 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Status changed from not yet recruiting to recruiting as reported by Vanderbilt-Ingram Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top